Increased Plasma Levels of Nesfatin-1 in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

 

 Permissions and Reprints

Abstract

Background:

Nesfatin-1, which is derived from nucleobindin2 (NUCB2), has been recently identified as a novel satiety regulator. However, its pathophysiological role in humans remains unknown. The aim of the present study was to investigate plasma nesfatin-1 levels and the association between plasma nesfatin-1 levels and various metabolic parameters in humans.

Materials and methods:

74 subjects with newly diagnosed type 2 diabetes mellitus (nT2DM), 73 subjects with impaired glucose tolerance (IGT) and 73 subjects with normal glucose tolerance (NGT) were enrolled in this study. Plasma nesfatin-1 levels were measured by a commercially available enzyme- linked immunosorbent assay.

Results:

Plasma nesfatin-1 levels were elevated in subjects with both nT2DM and IGT compared to controls (1.91±0.79 and 1.80±0.80 vs. 1.41±0.58 μ g/L, P<0.05 or P<0.01 ). Simple regression analysis showed that in subjects with IGT and nT2DM, plasma nesfatin-1 correlated positively with body mass index (BMI), hemoglobin A₁c (HbA_1c), fasting blood glucose (FBG), 2 h blood glucose after a glucose load (2hPBG), fasting plasma insulin (FINS) and the homeostasis model assessment of insulin resistance (HOMA-_IR). Multivariate logistic regression analysis revealed that plasma nesfatin-1 was significantly associated with IGT and nT2DM, even after controlling for differences in BMI.

Conclusion:

Plasma nesfatin-1 concentrations were found to be elevated in subjects with both IGT and nT2DM and to be related with several clinical parameters known to be associated with insulin resistance.

^*  These authors contributed equally to this project.

• References

• 1 Oh-I S, Shimizu H, Satoh T et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-712
  CrossrefPubMedGoogle Scholar
• 2 Johnstone LE, Fong TM, Leng G. Neuronal activation in the hypothalamus and brainstem during feeding in rats. Cell Metab 2006; 4: 257-258
  CrossrefPubMedGoogle Scholar
• 3 Stengel A, Goebel M, Wang L et al. Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology 2009; 150: 4911-4919
  CrossrefPubMedGoogle Scholar
• 4 Shimizu H, Oh-I S, Hashimoto K et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150: 662-671
  CrossrefPubMedGoogle Scholar
• 5 Kohno D, Nakata M, Maejima Y et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008; 149: 1295-1301
  CrossrefPubMedGoogle Scholar
• 6 Stengel A, Goebel M, Yakubov I et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009; 150: 232-238
  CrossrefPubMedGoogle Scholar
• 7 Goebel M, Stengel A, Wang L et al. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci Lett 2009; 452: 241-246
  CrossrefPubMedGoogle Scholar
• 8 Foo KS, Brauner H, Ostenson CG et al. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010; 204: 255-263
  CrossrefPubMedGoogle Scholar
• 9 Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Enodocrinol Metab 2008; 93: S64-S73
  PubMedGoogle Scholar
• 10 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553
  CrossrefPubMedGoogle Scholar
• 11 Albareda M, Rodriguez-Espinosi J, Murugo M et al. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000; 43: 1507-1511
  CrossrefPubMedGoogle Scholar
• 12 Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972; 8: 499-502
  PubMedGoogle Scholar
• 13 Ramanjaneya M, Chen J, Brown JE et al. Identification of nesfatin-1 in human and murine adipose tissue: A novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 1358-1363
  PubMedGoogle Scholar
• 14 Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?. Diabetes 1994; 43: 735-740
  PubMedGoogle Scholar
• 15 Li QC, Wang HY, Chen X et al. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010; 159: 72-77
  CrossrefPubMedGoogle Scholar
• 16 Gonzalez R, Tiwari A, Unniappan S. Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Bio Bio Res Commun 2009; 381: 643-648
  PubMedGoogle Scholar
• 17 Tan BK, Hallschmid M, Kern W et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/nucb-2, in obese human: evidence of nesfatin-1/nucb-2 resistance and implications for obesity treatment. JCEM 2011; 96: E669-E673
  PubMedGoogle Scholar
• 18 Ogiso K, Asakawa A, Amitani H et al. Plasma nesfatin-1 concentration in restricting-type anorexia nervosa. Peptide 2011; 32: 150-153
  PubMedGoogle Scholar
• 19 Aydin S, Dag E, Ozkan Y et al. Nesfatin-1and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009; 328: 49-56
  CrossrefPubMedGoogle Scholar